검색
EyePoint Pharmaceuticals Inc
EYPT관심 목록에 추가
12.190USD
-0.280-2.25%
종가 07-24 16:00（ET）시세는 15분 지연됩니다
1.01B시가총액
손실P/E TTM
자세한 내용은 EyePoint Pharmaceuticals Inc 회사
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Inc 정보
종목 코드 EYPT
회사 이름EyePoint Pharmaceuticals Inc
상장일Jan 27, 2005
CEODuker (Jay S)
직원 수165
유형Ordinary Share
회계 연도 종료Jan 27
주소480 Pleasant Street, Suite C400
도시WATERTOWN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02472
전화16179265000
웹사이트https://eyepointpharma.com/
종목 코드 EYPT
상장일Jan 27, 2005
CEODuker (Jay S)
EyePoint Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
--
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
60.00K
--
Dr. Goeran A. Ando, M.D.
Dr. Goeran A. Ando, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. George Elston
Mr. George Elston
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
--
자주 묻는 질문
EyePoint Pharmaceuticals Inc의 상위 5대 주주는 누구인가요?
EyePoint Pharmaceuticals Inc의 상위 5대 주주는 다음과 같습니다: Dr. Jay S. Duker, M.D.
EyePoint Pharmaceuticals Inc(EYPT)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, EyePoint Pharmaceuticals Inc의 주식을 보유한 기관은 총 381곳이며, 이들이 보유한 주식의 총 가치는 약 88.53M로 전체 발행 주식의 105.59%를 차지합니다. 이는 2025Q4 대비 -2754490.00 증가한 수치입니다.
EyePoint Pharmaceuticals Inc의 최대 수익원은 무엇인가요?
2026Q1 기준, EyePoint Pharmaceuticals Inc의 YUTIQ 부문이 가장 높은 매출을 기록했으며, 금액은 1.60M로 전체 매출의 5.10%를 차지했습니다.